These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 16322342)

  • 1. Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer.
    Melisi D; Caputo R; Damiano V; Bianco R; Veneziani BM; Bianco AR; De Placido S; Ciardiello F; Tortora G
    Endocr Relat Cancer; 2005 Dec; 12(4):1051-8. PubMed ID: 16322342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect.
    Tortora G; Caputo R; Damiano V; Melisi D; Bianco R; Fontanini G; Veneziani BM; De Placido S; Bianco AR; Ciardiello F
    Clin Cancer Res; 2003 Apr; 9(4):1566-72. PubMed ID: 12684433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonate zoledronic acid enhances the inhibitory effects of gefitinib on EGFR-mutated non-small cell lung carcinoma cells.
    Chang JW; Hsieh JJ; Shen YC; Yeh KY; Wang CH; Li YY; Hsu T
    Cancer Lett; 2009 Jun; 278(1):17-26. PubMed ID: 19233551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo.
    Bruzzese F; Di Gennaro E; Avallone A; Pepe S; Arra C; Caraglia M; Tagliaferri P; Budillon A
    Clin Cancer Res; 2006 Jan; 12(2):617-25. PubMed ID: 16428508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral administration of a novel taxane, an antisense oligonucleotide targeting protein kinase A, and the epidermal growth factor receptor inhibitor Iressa causes cooperative antitumor and antiangiogenic activity.
    Tortora G; Caputo R; Damiano V; Fontanini G; Melisi D; Veneziani BM; Zunino F; Bianco AR; Ciardiello F
    Clin Cancer Res; 2001 Dec; 7(12):4156-63. PubMed ID: 11751516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
    Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of the combination of docetaxel, zoledronic acid, and a COX-2 inhibitor on the growth of human breast cancer cell lines.
    Witters LM; Crispino J; Fraterrigo T; Green J; Lipton A
    Am J Clin Oncol; 2003 Aug; 26(4):S92-7. PubMed ID: 12902864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclooxygenase-2 inhibition: effects on tumour growth, cell cycling and lymphangiogenesis in a xenograft model of breast cancer.
    Barnes NL; Warnberg F; Farnie G; White D; Jiang W; Anderson E; Bundred NJ
    Br J Cancer; 2007 Feb; 96(4):575-82. PubMed ID: 17285134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
    Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
    Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model.
    Zhang X; Chen ZG; Choe MS; Lin Y; Sun SY; Wieand HS; Shin HJ; Chen A; Khuri FR; Shin DM
    Clin Cancer Res; 2005 Sep; 11(17):6261-9. PubMed ID: 16144930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zoledronic acid in combination with serine/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone-refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A.
    Cirak Y; Varol U; Atmaca H; Kisim A; Sezgin C; Karabulut B; Uzunoglu S; Uslu R; Karaca B
    BJU Int; 2012 Dec; 110(11 Pt C):E1147-54. PubMed ID: 22882676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
    Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
    Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of EGF-R signaling reduces the incidence of prostate cancer metastasis in nude mice.
    Angelucci A; Gravina GL; Rucci N; Millimaggi D; Festuccia C; Muzi P; Teti A; Vicentini C; Bologna M
    Endocr Relat Cancer; 2006 Mar; 13(1):197-210. PubMed ID: 16601288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo.
    Ottewell PD; Deux B; Mönkkönen H; Cross S; Coleman RE; Clezardin P; Holen I
    Clin Cancer Res; 2008 Jul; 14(14):4658-66. PubMed ID: 18628481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased anti-tumour effects of doxorubicin and zoledronic acid in prostate cancer cells in vitro: supporting the benefits of combination therapy.
    Clyburn RD; Reid P; Evans CA; Lefley DV; Holen I
    Cancer Chemother Pharmacol; 2010 Apr; 65(5):969-78. PubMed ID: 19730863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer.
    Dominguez-Escrig JL; Kelly JD; Neal DE; King SM; Davies BR
    Clin Cancer Res; 2004 Jul; 10(14):4874-84. PubMed ID: 15269164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting cyclooxygenase-2 and the epidermal growth factor receptor for the prevention and treatment of intestinal cancer.
    Buchanan FG; Holla V; Katkuri S; Matta P; DuBois RN
    Cancer Res; 2007 Oct; 67(19):9380-8. PubMed ID: 17909047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gefitinib-trastuzumab combination on hormone-refractory prostate cancer xenograft.
    Formento P; Hannoun-Levi JM; Gérard F; Mazeau C; Fischel JL; Etienne-Grimaldi MC; Gugenheim J; Milano G
    Eur J Cancer; 2005 Jul; 41(10):1467-73. PubMed ID: 15919200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multifunctional role of VIP in prostate cancer progression in a xenograft model: suppression by curcumin and COX-2 inhibitor NS-398.
    Fernández-Martínez AB; Bajo AM; Valdehita A; Isabel Arenas M; Sánchez-Chapado M; Carmena MJ; Prieto JC
    Peptides; 2009 Dec; 30(12):2357-64. PubMed ID: 19772879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.